Drugs / NK510
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT07083349 | Dec 2025 → Apr 2026 | systemic lupus erythematosus | Base Therapeutics (Shanghai) Co., Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT07166263 | Oct 2025 → Jun 2027 expected | colorectal cancer, gastric cancer | Base Therapeutics (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 0 | NCT06098898 | Nov 2023 → Nov 2024 | gastric cancer | Base Therapeutics (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT06097962 | Jul 2023 → Jul 2027 expected | non-small cell lung carcinoma | Base Therapeutics (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 0 | NCT06117878 | Sep 2022 → Sep 2024 | osteosarcoma, soft tissue sarcoma | Base Therapeutics (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NK510 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07083349 ↗ |
| Action | Inhibit | “TIGIT-Blocked NK510 Cells” NCT06097962 ↗ |
| Modality | Cell therapy | “TIGIT-Blocked NK510 Cells” NCT06097962 ↗ |
| Route | Intravenous | “administered through intravenous infusion.” NCT06098898 ↗ |
| Target | TIGIT | “TIGIT-Blocked NK510 Cells” NCT06097962 ↗ |